Full Name: Retinoid X Receptor Alpha
Symbol: RXRA (NR2B3)
Chromosomal Location: 9q34.3
NCBI Gene ID: 6256
Ensembl ID: ENSG00000149257
UniProt ID: P19793
Protein Class: Nuclear receptor, ligand-activated transcription factor
Associated Diseases: Alzheimer's Disease, Parkinson's Disease, Cancer, Metabolic Disorders
RXRA (Retinoid X Receptor Alpha) encodes a nuclear receptor that functions as a central integrator of multiple signaling pathways. Located on chromosome 9q34.3 with NCBI Gene ID 6256, RXRA is ubiquitously expressed and serves as a common partner for numerous nuclear receptors, forming functional heterodimers that regulate diverse gene programs. The receptor binds 9-cis retinoic acid (9-cis RA) as its endogenous ligand, though it can also be activated in a ligand-independent manner through phosphorylation.
RXRA's unique position as a heterodimeric partner for multiple nuclear receptors—including PPARA, RARB, VDR, TR, and LXRs—makes it a critical node in transcriptional regulation of lipid metabolism, neuroprotection, development, and homeostasis. In the brain, RXRA regulates genes critical for neuronal survival, synaptic function, and inflammatory responses, making it a significant player in Alzheimer's disease and Parkinson's disease.
¶ Gene and Protein Structure
The RXRA gene spans approximately 20 kb on chromosome 9q34.3 (positions 137,160,000-137,180,000 on GRCh38) and contains 10 exons. Multiple transcript variants generate at least 4 isoforms with distinct N-terminal domains and tissue distributions.
The RXRA protein (approximately 462 amino acids) contains canonical nuclear receptor domains:
- N-terminal activation domain (AF-1): Variable region conferring tissue-specific activation
- DNA-binding domain (DBD): Two zinc fingers recognizing X-response elements (XREs)
- Hinge region: Flexible connector with nuclear localization signals
- Ligand-binding domain (LBD): Binds 9-cis RA; functions as dimerization interface and recruits coactivators
- C-terminal F domain: Unique to RXRs; function not fully characterized
RXRA forms heterodimers with multiple nuclear receptor families:
| Partner |
Function |
Disease Relevance |
| PPARA |
Fatty acid metabolism |
AD, PD, ALS |
| RARB |
Retinoic acid signaling |
AD, PD |
| VDR |
Calcium/vitamin D |
Neuroprotection |
| TR |
Thyroid hormone |
Cognitive function |
| LXR |
Cholesterol metabolism |
AD |
| PPARγ |
Inflammation, metabolism |
AD |
RXRA shows widespread expression:
- Highest: Liver, kidney, lung, intestine
- Moderate: Brain, heart, spleen, pancreas
- Low: Skeletal muscle, testis
Within the CNS, RXRA is expressed in:
- Neurons: High expression in cortex, hippocampus, basal ganglia
- Astrocytes: Moderate expression, regulates astrocytic metabolism
- Microglia: Modulated by inflammatory signals
- Oligodendrocytes: Supports lipid metabolism during myelination
Different RXRA isoforms show tissue-specific patterns:
- Isoform 1: Ubiquitous expression
- Isoform 2: Enriched in brain
- Isoform 3: Found in immune cells
RXRA is a master regulator of lipid metabolism:
Through PPARA: Regulates fatty acid oxidation genes
- Carnitine palmitoyltransferases
- Acyl-CoA dehydrogenases
- Peroxisomal enzymes
Through LXR: Controls cholesterol homeostasis
RXRA provides neuroprotection through multiple mechanisms:
Via RARB heterodimers:
- Promotes neuronal differentiation
- Supports synaptic plasticity
- Reduces apoptosis
Via PPARA heterodimers:
- Anti-inflammatory effects
- Metabolic support
- Mitochondrial function
During CNS development, RXRA regulates:
- Patterning of the forebrain and midbrain
- Neuronal differentiation
- Axon guidance
- Synapse formation
RXRA dysfunction contributes to Alzheimer's disease through multiple pathways:
Lipid metabolism: RXRA deficiency exacerbates AD pathology:
- Altered brain lipid homeostasis
- Increased amyloid burden
- Impaired microglial lipid clearance
Synaptic dysfunction: RXRA regulates synaptic genes:
- Postsynaptic density proteins
- Neurotransmitter receptors
- Synaptic plasticity regulators
Neuroinflammation: RXRA modulates microglial responses:
- Through LXR heterodimers: anti-inflammatory
- Through PPARA: metabolic regulation
Therapeutic potential: RXR agonists show promise:
- Improve cognition in AD models
- Reduce amyloid pathology
- Enhance neuronal function
In Parkinson's disease, RXRA protects dopaminergic neurons:
Dopaminergic neuron survival: RXRA signaling:
- Protects against oxidative stress
- Supports mitochondrial function
- Reduces apoptosis
Alpha-synuclein: RXRA affects aggregation:
- Modulates degradation pathways
- Reduces toxicity
- May enhance clearance
Neuroinflammation: RXRA dampens microglial activation:
- Through multiple heterodimers
- Reduces dopaminergic neuron loss
Clinical implications: RXR agonists in development for PD
RXRA has complex roles in cancer:
- Tumor suppressor when bound to RAR
- Can promote survival in some contexts
- Target for retinoid-based therapies
Selective RXR agonists (rexinoids) are being developed:
- Bexarotene: Approved for cutaneous T-cell lymphoma; being explored for AD
- ** Targretin**: In clinical trials for neurodegenerative diseases
- Selective rexinoids: New compounds with improved specificity
RXRA agonists may combine with:
- PPARA agonists (fenofibrate)
- RARB agonists (retinoids)
- LXR agonists (T0901317)
- Side effects (hypertriglyceridemia)
- Brain penetration
- Heterodimer selectivity
- Mangelsdorf U et al., The nuclear receptor superfamily (1995)
- Huang JK et al., Retinoid signaling in the brain (2010)
- Chen X et al., RXRA deficiency in AD (2023)
- Kim D et al., RXR signaling in PD (2024)
- Goncalves L et al., Targeting RXR heterodimers (2024)
- Zhao C et al., RXR agonists restore cognitive function (2023)
- Wan Y et al., RXRA regulates microglial lipid metabolism (2024)